No photo of Patrick Kiser

View Scopus Profile

Patrick Kiser

  • 2960 Citations
1990 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research Interests

The primary focus of the Kiser research group is developing and translating new drug delivery technologies for the prevention and treatment of HIV infection. We are particularly interested in new antiviral agents and drug delivery systems to intercept sexually transmitted viruses at the point of interaction with the genital mucosa and the first target cells infected in the mucosa. Our methods include synthetic polymer chemistry, pharmaceutical chemistry, modeling drug transport, and using these results in drug delivery system design and prototyping. We perform preclinical toxicity efficacy evaluations in cell, tissue, and animal models; conduct antiviral assays and drug transport assays; and produce devices using a variety of pharmaceutical manufacturing technologies. Our projects range from new materials discovery that could lead to next generation mucosally active antiviral agents and mucosal vaccines, to the development of new assays to evaluate HIV prevention technologies, to sustained delivery system projects for antiviral, anti-infectives and contraceptive agents. The lab is funded by the NIH (NIAD), the Bill and Melinda Gates Foundation and USAID.

Education/Academic qualification

Mechanical Engineering and Materials Science, PhD, Duke University

… → 1999

MS, University of Wisconsin-Milwaukee

… → 1989

Chemistry and Philosophy, BS, University of Wisconsin-Madison

Fingerprint Dive into the research topics where Patrick Kiser is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants

Subproject for Dr. Patrick Kiser for the study titled "Harnessing MUC16-IgG Interactions to Enhance HIV Vaccine Function".

Kiser, P.

National Institute of Allergy and Infectious Diseases

6/16/16 → 5/31/21

Project: Research project

    • Identification of new LAT-1 transporter substrates for drug delivery

    Kiser, P.

    University of Nebraska at Kearney, National Institute of Neurological Disorders and Stroke

    9/18/17 → 8/31/19

    Project: Research project

    • Next-generation products for prevention of HIV infection in women (Project NIX HIV)

    Kiser, P.

    Eastern Virginia Medical School, Agency for International Development

    9/15/17 → 2/29/20

    Project: Research project

    • Development and clinical evaluation of a synthetic mucin-like polymer gel as a novel vaginal contraceptive

    Kiser, P.

    Eastern Virginia Medical School, Bill & Melinda Gates Foundation

    2/1/17 → 1/31/19

    Project: Research project

    • A Multi Facility Mass Spectrometer for Targeted Quantitation Experiments

    Avram, M. J., Bass, J., Habibi Goudarzi, S., Kandela, I., Kelleher, N. L., Kiser, P., Krejcie, T. C., Mazar, A. P., Ott, A. W., Schiltz, G. E., Siddique, T., Thomas, P. M., Tyo, K. E. J., Wainwright, D. A., Watterson, D. M. & Woodruff, T. K.

    Office of the Director, National Institutes of Health

    7/15/16 → 7/14/18

    Project: Research project

    • Research Output

    A subcutaneous implant of tenofovir alafenamide fumarate causes local inflammation and tissue necrosis in rabbits and macaques

    Su, J. T., Simpson, S. M., Sung, S., Tfaily, E. B., Veazey, R., Marzinke, M., Qiu, J., Watrous, D., Widanapathirana, L., Pearson, E., Peet, M. M., Karunakaran, D., Grasperge, B., Dobek, G., Cain, C. M., Hope, T. & Kiser, P. F., Jan 1 2020, In : Antimicrobial agents and chemotherapy. 64, 3, e01893.

    Research output: Contribution to journal › Article

    Open Access

    • Design of a Drug-Eluting Subcutaneous Implant of the Antiretroviral Tenofovir Alafenamide Fumarate

    Simpson, S. M., Widanapathirana, L., Su, J. T., Sung, S., Watrous, D., Qiu, J., Pearson, E., Evanoff, A., Karunakaran, D., Chacon, J. E. & Kiser, P. F., Apr 1 2020, In : Pharmaceutical Research. 37, 4, 83.

    Research output: Contribution to journal › Article

    Open Access

    • Qualitative consumer research on acceptance of long-acting pre-exposure prophylaxis products among men having sex with men and medical practitioners in the United States

    Calder, B. J., Schieffer, R. J., Bryndza Tfaily, E., D'Aquila, R., Greene, G. J., Carballo-Diéguez, A., Giguere, R., Kiser, P. F. & Hope, T. J., Oct 2018, In : AIDS research and human retroviruses. 34, 10, p. 849-856 8 p.

    Research output: Contribution to journal › Article

    • 3 Scopus citations

    Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women

    Thurman, A. R., Schwartz, J. L., Brache, V., Clark, M. R., McCormick, T., Chandra, N., Marzinke, M. A., Stanczyk, F. Z., Dezzutti, C. S., Hillier, S. L., Herold, B. C., Fichorova, R., Asin, S. N., Rollenhagen, C., Weiner, D., Kiser, P. & Doncel, G. F., Jun 2018, In : PloS one. 13, 6, e0199778.

    Research output: Contribution to journal › Article

    • 15 Scopus citations

    A Dose Ranging Pharmacokinetic Evaluation of IQP-0528 Released from Intravaginal Rings in Non-Human Primates

    Su, J. T., Teller, R. S., Srinivasan, P., Zhang, J., Martin, A., Sung, S., Smith, J. M. & Kiser, P. F., Oct 1 2017, In : Pharmaceutical Research. 34, 10, p. 2163-2171 9 p.

    Research output: Contribution to journal › Article

    • 2 Scopus citations